{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T06:50:38Z","timestamp":1790923838044,"version":"4.1.0"},"reference-count":204,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002387","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA169300"],"award-info":[{"award-number":["R01 CA169300"]}],"id":[{"id":"10.13039\/501100002387","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.pharmthera.2015.08.007","type":"journal-article","created":{"date-parts":[[2015,8,20]],"date-time":"2015-08-20T02:32:34Z","timestamp":1440037954000},"page":"105-116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":186,"special_numbering":"C","title":["Cathepsin L targeting in cancer treatment"],"prefix":"10.1016","volume":"155","author":[{"given":"Dhivya R.","family":"Sudhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar W.","family":"Siemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2015.08.007_bb0005","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0304-3835(95)03930-U","article-title":"Cathepsin B, L, and D activities in colorectal carcinomas: relationship with clinico-pathological parameters","volume":"96","author":"Adenis","year":"1995","journal-title":"Cancer Lett"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4236\/jct.2013.46A2001","article-title":"Assessment of the roles of cathepsins B, H and L in the progression of colorectal cancer","volume":"4","author":"Anestakis Doxakis","year":"2013","journal-title":"J Cancer Ther"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0015","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1046\/j.1523-1755.2002.00539.x","article-title":"Selective modulation of the secretion of proteinases and their inhibitors by growth factors in cultured differentiated podocytes","volume":"62","author":"Asanuma","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0020","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1042\/BJ20110361","article-title":"Procathepsin L secretion, which triggers tumour progression, is regulated by Rab4a in human melanoma cells","volume":"437","author":"Barbarin","year":"2011","journal-title":"Biochem J"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0025","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1042\/bj2520301","article-title":"Human kidney cathepsins B and L. Characterization and potential role in degradation of glomerular basement membrane","volume":"252","author":"Baricos","year":"1988","journal-title":"Biochem J"},{"issue":"Pt C","key":"10.1016\/j.pharmthera.2015.08.007_bb0030","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0076-6879(81)80043-2","article-title":"Cathepsin B, Cathepsin H, and cathepsin L","volume":"80","author":"Barrett","year":"1981","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0035","doi-asserted-by":"crossref","first-page":"7378","DOI":"10.1158\/0008-5472.CAN-07-0602","article-title":"Inhibition of cysteine cathepsin protease activity enhances chemotherapy regimens by decreasing tumor growth and invasiveness in a mouse model of multistage cancer","volume":"67","author":"Bell-McGuinn","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0040","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/nchembio.2007.26","article-title":"Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes","volume":"3","author":"Blum","year":"2007","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1040-8428(01)00196-2","article-title":"Cell-surface proteolysis, growth factor activation and intercellular communication in the progression of melanoma","volume":"44","author":"Bogenrieder","year":"2002","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0050","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nsmb.1831","article-title":"53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers","volume":"17","author":"Bouwman","year":"2010","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0055","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00441-009-0887-6","article-title":"Proteinases involved in matrix turnover during cartilage and bone breakdown","volume":"339","author":"Cawston","year":"2010","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0060","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/mc.2940050311","article-title":"Increased expression of cathepsins L and B and decreased activity of their inhibitors in metastatic, ras-transformed NIH 3T3 cells","volume":"5","author":"Chambers","year":"1992","journal-title":"Mol Carcinog"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0065","first-page":"1478","article-title":"Expression of cathepsin L in human tumors","volume":"51","author":"Chauhan","year":"1991","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0070","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ejmech.2012.10.039","article-title":"Initial evaluation of the antitumour activity of KGP94, a functionalized benzophenone thiosemicarbazone inhibitor of cathepsin L","volume":"58","author":"Chavarria","year":"2012","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0075","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s00432-013-1424-2","article-title":"Microarray analyses reveal liver metastasis-related genes in metastatic colorectal cancer cell model","volume":"139","author":"Chen","year":"2013","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0080","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3892\/ol.2011.302","article-title":"Detection of cathepsin B, cathepsin L, cystatin C, urokinase plasminogen activator and urokinase plasminogen activator receptor in the sera of lung cancer patients","volume":"2","author":"Chen","year":"2011","journal-title":"Oncol Lett"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0085","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/bcr2835","article-title":"Therapeutic targets for bone metastases in breast cancer","volume":"13","author":"Clezardin","year":"2011","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0090","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/10520290400010572","article-title":"Matrigel invasion by the prostate cancer cell lines, PC3 and DU145, and cathepsin L+B activity","volume":"79","author":"Colella","year":"2004","journal-title":"Biotech Histochem"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0095","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1126\/science.1067100","article-title":"Matrix metalloproteinase inhibitors and cancer: trials and tribulations","volume":"295","author":"Coussens","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0100","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1601-0825.2005.01153.x","article-title":"Collagen degradation by interleukin-1beta-stimulated gingival fibroblasts is accompanied by release and activation of multiple matrix metalloproteinases and cysteine proteinases","volume":"12","author":"Cox","year":"2006","journal-title":"Oral Dis"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0105","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1023\/A:1018428105463","article-title":"Exposure to hypoxia, glucose starvation and acidosis: effect on invasive capacity of murine tumor cells and correlation with cathepsin (L+B) secretion","volume":"15","author":"Cuvier","year":"1997","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0110","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1006\/cyto.1999.0593","article-title":"Cysteine protease production by human osteosarcoma cells (MG63, SAOS2) and its modulation by soluble factors","volume":"12","author":"Damiens","year":"2000","journal-title":"Cytokine"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0115","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/S0002-9440(10)63200-2","article-title":"Proteases, extracellular matrix, and cancer: a workshop of the path B study section","volume":"164","author":"DeClerck","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0120","first-page":"55","article-title":"Cysteine proteinase cathepsin L expression correlates closely with the metastatic potential of H-ras-transformed murine fibroblasts","volume":"2","author":"Denhardt","year":"1987","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0125","first-page":"4590","article-title":"Close relationship of the major excreted protein of transformed murine fibroblasts to thiol-dependent cathepsins","volume":"46","author":"Denhardt","year":"1986","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0130","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1515\/bc.2010.097","article-title":"Impaired turnover of autophagolysosomes in cathepsin L deficiency","volume":"391","author":"Dennemarker","year":"2010","journal-title":"Biol Chem"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0135","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/sj.gene.6364132","article-title":"DNA microarray allows molecular profiling of rheumatoid arthritis and identification of pathophysiological targets","volume":"5","author":"Devauchelle","year":"2004","journal-title":"Genes Immun"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0140","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/1097-0142(20000801)89:3<482::AID-CNCR2>3.0.CO;2-5","article-title":"Immunostained cathepsins B and L correlate with depth of invasion and different metastatic pathways in early stage gastric carcinoma","volume":"89","author":"Dohchin","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0145","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1128\/MCB.5.3.466","article-title":"Malignant transformation and tumor promoter treatment increase levels of a transcript for a secreted glycoprotein","volume":"5","author":"Doherty","year":"1985","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0150","doi-asserted-by":"crossref","first-page":"7377","DOI":"10.1016\/S0021-9258(18)83244-6","article-title":"Mechanism for selective secretion of a lysosomal protease by transformed mouse fibroblasts","volume":"264","author":"Dong","year":"1989","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0155","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/j.biochi.2010.04.023","article-title":"Identification and pre-clinical testing of a reversible cathepsin protease inhibitor reveals anti-tumor efficacy in a pancreatic cancer model","volume":"92","author":"Elie","year":"2010","journal-title":"Biochimie"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0160","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1359\/jbmr.060614","article-title":"Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone","volume":"21","author":"Everts","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0165","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1093\/carcin\/17.12.2581","article-title":"Increased levels of cathepsin B and L, urokinase-type plasminogen activator and its inhibitor type-1 as an early event in gastric carcinogenesis","volume":"17","author":"Farinati","year":"1996","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0170","doi-asserted-by":"crossref","first-page":"7883","DOI":"10.1073\/pnas.112632299","article-title":"Neuronal loss and brain atrophy in mice lacking cathepsins B and L","volume":"99","author":"Felbor","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0175","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2174\/138161207779313551","article-title":"Matrix metalloproteinases as valid clinical targets","volume":"13","author":"Fingleton","year":"2007","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0180","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s10555-006-7894-9","article-title":"Recent advances in MMP inhibitor design","volume":"25","author":"Fisher","year":"2006","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0185","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1200\/JCO.1998.16.3.1013","article-title":"Prognostic significance of cathepsins B and L in primary human breast cancer","volume":"16","author":"Foekens","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0190","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00198-003-1508-y","article-title":"Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2years of goserelin or 6months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF)","volume":"14","author":"Fogelman","year":"2003","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0195","first-page":"2733","article-title":"Procathepsin-L, a proteinase that cleaves human C3 (the third component of complement), confers high tumorigenic and metastatic properties to human melanoma cells","volume":"58","author":"Frade","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0200","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/cgt.2008.51","article-title":"Intratumoral gene delivery of anti-cathepsin L single-chain variable fragment by lentiviral vector inhibits tumor progression induced by human melanoma cells","volume":"15","author":"Frade","year":"2008","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0205","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1128\/MCB.5.10.2582","article-title":"Regulation of the transcript for a lysosomal protein: evidence for a gene program modified by platelet-derived growth factor","volume":"5","author":"Frick","year":"1985","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0210","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0959-8049(98)00273-1","article-title":"Cathepsins B, H, L and cysteine protease inhibitors in malignant prostate cell lines, primary cultured prostatic cells and prostatic tissue","volume":"35","author":"Friedrich","year":"1999","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0215","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1002\/1097-0142(20010301)91:5<972::AID-CNCR1087>3.0.CO;2-Q","article-title":"Activity, expression, and transcription rate of the cathepsins B, D, H, and L in cutaneous malignant melanoma","volume":"91","author":"Frohlich","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0220","doi-asserted-by":"crossref","first-page":"35652","DOI":"10.1074\/jbc.M709010200","article-title":"Major role of cathepsin L for producing the peptide hormones ACTH, beta-endorphin, and alpha-MSH, illustrated by protease gene knockout and expression","volume":"283","author":"Funkelstein","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0225","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0039-128X(00)00097-0","article-title":"Regulation of collagenolytic cysteine protease synthesis by estrogen in osteoclasts","volume":"65","author":"Furuyama","year":"2000","journal-title":"Steroids"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0230","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1006\/bbrc.2000.2698","article-title":"Regulation of collagenolytic protease secretion through c-Src in osteoclasts","volume":"272","author":"Furuyama","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0235","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0021-9258(17)36004-0","article-title":"The major excreted protein of transformed fibroblasts is an activable acid-protease","volume":"261","author":"Gal","year":"1986","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0240","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1042\/bj2530303","article-title":"Isolation and sequence of a cDNA for human pro-(cathepsin L)","volume":"253","author":"Gal","year":"1988","journal-title":"Biochem J"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0245","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1083\/jcb.100.2.535","article-title":"Processing and lysosomal localization of a glycoprotein whose secretion is transformation stimulated","volume":"100","author":"Gal","year":"1985","journal-title":"J Cell Biol"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0250","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/jnen\/60.9.847","article-title":"Cathepsins are upregulated by IFN-gamma\/STAT1 in human muscle culture: a possible active factor in dermatomyositis","volume":"60","author":"Gallardo","year":"2001","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0255","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1089\/107999001459114","article-title":"Interleukin-6 and transforming growth factor-beta 1 control expression of cathepsins B and L in human lung epithelial cells","volume":"21","author":"Gerber","year":"2001","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0260","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1515\/BC.2008.035","article-title":"Inhibitory effect of the sugarcane cystatin CaneCPI-4 on cathepsins B and L and human breast cancer cell invasion","volume":"389","author":"Gianotti","year":"2008","journal-title":"Biol Chem"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0265","doi-asserted-by":"crossref","first-page":"60","DOI":"10.4161\/cc.6.1.3669","article-title":"Cysteine cathepsins and the cutting edge of cancer invasion","volume":"6","author":"Gocheva","year":"2007","journal-title":"Cell Cycle"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0270","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1101\/gad.1407406","article-title":"Distinct roles for cysteine cathepsin genes in multistage tumorigenesis","volume":"20","author":"Gocheva","year":"2006","journal-title":"Genes Dev"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0275","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1038\/emboj.2011.225","article-title":"A new pathway that regulates 53BP1 stability implicates cathepsin L and vitamin D in DNA repair","volume":"30","author":"Gonzalez-Suarez","year":"2011","journal-title":"EMBO J"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0280","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/0014-5793(92)80339-I","article-title":"Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L","volume":"297","author":"Goretzki","year":"1992","journal-title":"FEBS Lett"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0285","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/BF00315829","article-title":"Localization of cathepsins B, D, and L in the rat osteoclast by immuno-light and -electron microscopy","volume":"101","author":"Goto","year":"1994","journal-title":"Histochemistry"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0290","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/BF00717054","article-title":"Immunohistochemical localization of cathepsins B, D and L in the rat osteoclast","volume":"99","author":"Goto","year":"1993","journal-title":"Histochemistry"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0295","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1073\/pnas.75.6.2767","article-title":"Transformation-dependent secretion of a low molecular weight protein by murine fibroblasts","volume":"75","author":"Gottesman","year":"1978","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0300","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/0092-8674(80)90519-X","article-title":"Tumor promoters and Kirsten sarcoma virus increase synthesis of a secreted glycoprotein by regulating levels of translatable mRNA","volume":"19","author":"Gottesman","year":"1980","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0305","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1097-2765(04)00209-6","article-title":"A cathepsin L isoform that is devoid of a signal peptide localizes to the nucleus in S phase and processes the CDP\/Cux transcription factor","volume":"14","author":"Goulet","year":"2004","journal-title":"Mol Cell"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0310","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1158\/1541-7786.MCR-07-0160","article-title":"Increased expression and activity of nuclear cathepsin L in cancer cells suggests a novel mechanism of cell transformation","volume":"5","author":"Goulet","year":"2007","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0315","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1515\/BC.2006.159","article-title":"A novel proteolytically processed CDP\/Cux isoform of 90kDa is generated by cathepsin L","volume":"387","author":"Goulet","year":"2006","journal-title":"Biol Chem"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0320","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1083\/jcb.201204053","article-title":"BRCA1 loss activates cathepsin L-mediated degradation of 53BP1 in breast cancer cells","volume":"200","author":"Grotsky","year":"2013","journal-title":"J Cell Biol"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0325","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.cell.2006.11.001","article-title":"Cancer metastasis: building a framework","volume":"127","author":"Gupta","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0330","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1093\/annonc\/mdr017","article-title":"Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment","volume":"22","author":"Hadji","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0335","first-page":"2757","article-title":"Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy","volume":"7","author":"Harbeck","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0340","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1135::AID-CNCR6>3.0.CO;2-2","article-title":"The role of cysteine and serine proteases in colorectal carcinoma","volume":"86","author":"Herszenyi","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0345","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0304-3835(95)04041-2","article-title":"Nuclear localization of procathepsin L\/MEP in ras-transformed mouse fibroblasts","volume":"99","author":"Hiwasa","year":"1996","journal-title":"Cancer Lett"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0350","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.beem.2008.06.001","article-title":"Epidemiology of osteoporosis","volume":"22","author":"Holroyd","year":"2008","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0355","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.2337\/diabetes.52.9.2411","article-title":"Impaired cathepsin L gene expression in skeletal muscle is associated with type 2 diabetes","volume":"52","author":"Huang","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0360","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/mc.20362","article-title":"Cathepsins and osteosarcoma: expression analysis identifies cathepsin K as an indicator of metastasis","volume":"47","author":"Husmann","year":"2008","journal-title":"Mol Carcinog"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0365","doi-asserted-by":"crossref","first-page":"9556","DOI":"10.1074\/jbc.M605510200","article-title":"Cathepsin L expression is directed to secretory vesicles for enkephalin neuropeptide biosynthesis and secretion","volume":"282","author":"Hwang","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0370","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.canlet.2004.09.053","article-title":"Prostate cancer mediates osteoclastogenesis through two different pathways","volume":"223","author":"Inoue","year":"2005","journal-title":"Cancer Lett"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0375","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1006\/bbrc.1995.2820","article-title":"Procathepsin L degrades extracellular matrix proteins in the presence of glycosaminoglycans in vitro","volume":"217","author":"Ishidoh","year":"1995","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0380","first-page":"1","article-title":"Prognostic and predictive value of cathepsins D and L in operable breast cancer patients","volume":"52","author":"Jagodic","year":"2005","journal-title":"Neoplasma"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0390","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s00277-010-1012-3","article-title":"Cathepsins B and L in peripheral blood mononuclear cells of pediatric acute myeloid leukemia: potential poor prognostic markers","volume":"89","author":"Jain","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0395","first-page":"254","article-title":"A cysteine proteinase, which cleaves human C3, the third component of complement, is involved in tumorigenicity and metastasis of human melanoma","volume":"56","author":"Jean","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0400","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1042\/bj3610173","article-title":"Characterization of human cathepsin L promoter and identification of binding sites for NF-Y, Sp1 and Sp3 that are essential for its activity","volume":"361","author":"Jean","year":"2002","journal-title":"Biochem J"},{"issue":"Pt 3","key":"10.1016\/j.pharmthera.2015.08.007_bb0405","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1042\/bj3120961","article-title":"Identification on melanoma cells of p39, a cysteine proteinase that cleaves C3, the third component of complement: amino-acid-sequence identities with procathepsin L","volume":"312","author":"Jean","year":"1995","journal-title":"Biochem J"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0410","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/sj.onc.1209196","article-title":"Expression of cathepsin L in human tumor cells is under the control of distinct regulatory mechanisms","volume":"25","author":"Jean","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0420","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3816\/CBC.2010.n.059","article-title":"The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial","volume":"10","author":"Jensen","year":"2010","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0425","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1535-6108(04)00111-4","article-title":"Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis","volume":"5","author":"Joyce","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0430","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nrc2618","article-title":"Microenvironmental regulation of metastasis","volume":"9","author":"Joyce","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0435","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/BF01105077","article-title":"Biochemical and immunohistochemical analysis of cathepsins B, H, L and D in human melanocytic tumours","volume":"287","author":"Kageshita","year":"1995","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0440","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/0014-5793(95)00790-G","article-title":"Secretion and processing mechanisms of procathepsin L in bone resorption","volume":"370","author":"Kakegawa","year":"1995","journal-title":"FEBS Lett"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0445","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2183\/pjab.87.29","article-title":"Structure-based development of specific inhibitors for individual cathepsins and their medical applications","volume":"87","author":"Katunuma","year":"2011","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0450","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1006\/abbi.2001.2709","article-title":"Structure-based design of specific cathepsin inhibitors and their application to protection of bone metastases of cancer cells","volume":"397","author":"Katunuma","year":"2002","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0455","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0065-2571(01)00060-7","article-title":"Structure-based development of cathepsin L inhibitors and therapeutic applications for prevention of cancer metastasis and cancer-induced osteoporosis","volume":"42","author":"Katunuma","year":"2002","journal-title":"Adv Enzyme Regul"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0460","doi-asserted-by":"crossref","first-page":"27701","DOI":"10.1074\/jbc.M109.031849","article-title":"p110 CUX1 homeodomain protein stimulates cell migration and invasion in part through a regulatory cascade culminating in the repression of E-cadherin and occludin","volume":"284","author":"Kedinger","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0465","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.gene.2007.05.002","article-title":"Transcriptional upregulation of human cathepsin L by VEGF in glioblastoma cells","volume":"399","author":"Keerthivasan","year":"2007","journal-title":"Gene"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0470","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/jcb.10662","article-title":"Prostate cancer bone metastases promote both osteolytic and osteoblastic activity","volume":"91","author":"Keller","year":"2004","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0475","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.3747\/co.2008.174","article-title":"Cancer treatment-related bone loss: a review and synthesis of the literature","volume":"15","author":"Khan","year":"2008","journal-title":"Curr Oncol"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0480","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0959-8049(00)00014-9","article-title":"Antisense RNA inhibition of cathepsin L expression reduces tumorigenicity of malignant cells","volume":"36","author":"Kirschke","year":"2000","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0485","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1042\/bj2010367","article-title":"Action of rat liver cathepsin L on collagen and other substrates","volume":"201","author":"Kirschke","year":"1982","journal-title":"Biochem J"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0490","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.bmcl.2009.12.090","article-title":"Design, synthesis, and biological evaluation of potent thiosemicarbazone based cathepsin L inhibitors","volume":"20","author":"Kishore Kumar","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0495","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/sj.cgt.7700341","article-title":"Cathepsin L antisense oligonucleotides in a human osteosarcoma cell line: effects on the invasive phenotype","volume":"8","author":"Krueger","year":"2001","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0500","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.bbamcr.2009.09.016","article-title":"Avoiding spam in the proteolytic Internet: future strategies for anti-metastatic MMP inhibition","volume":"1803","author":"Kruger","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0505","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1016\/j.bmcl.2010.09.026","article-title":"Functionalized benzophenone, thiophene, pyridine, and fluorene thiosemicarbazone derivatives as inhibitors of cathepsin L","volume":"20","author":"Kumar","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0510","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/BF01806189","article-title":"Cathepsins D, B, and L in transformed human breast epithelial cells","volume":"39","author":"Lah","year":"1996","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0515","first-page":"578","article-title":"Cathepsin B, a prognostic indicator in lymph node-negative breast carcinoma patients: comparison with cathepsin D, cathepsin L, and other clinical indicators","volume":"6","author":"Lah","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0520","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1517\/14712598.6.3.257","article-title":"Antiprotease therapy in cancer: hot or not?","volume":"6","author":"Lah","year":"2006","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0525","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0014-5793(95)00287-J","article-title":"Gamma-interferon causes a selective induction of the lysosomal proteases, cathepsins B and L, in macrophages","volume":"363","author":"Lah","year":"1995","journal-title":"FEBS Lett"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0530","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0046-8177(00)80214-2","article-title":"Cells producing cathepsins D, B, and L in human breast carcinoma and their association with prognosis","volume":"31","author":"Lah","year":"2000","journal-title":"Hum Pathol"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0535","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/BF02907801","article-title":"The expression of lysosomal proteinases and their inhibitors in breast cancer: possible relationship to prognosis of the disease","volume":"3","author":"Lah","year":"1997","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0540","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.lab.2004.06.001","article-title":"Soluble cathepsin-L: a marker of bone resorption and bone density?","volume":"144","author":"Lang","year":"2004","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0545","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.lfs.2009.11.016","article-title":"Cathepsin L, target in cancer treatment?","volume":"86","author":"Lankelma","year":"2010","journal-title":"Life Sci"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0550","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/jb\/mvj037","article-title":"Processing of human cathepsin D is independent of its catalytic function and auto-activation: involvement of cathepsins L and B","volume":"139","author":"Laurent-Matha","year":"2006","journal-title":"J Biochem"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0555","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/rheumatology\/36.7.735","article-title":"Selective induction of the secretion of cathepsins B and L by cytokines in synovial fibroblast-like cells","volume":"36","author":"Lemaire","year":"1997","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0560","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1515\/bc.2010.069","article-title":"Cathepsin L in metastatic bone disease: therapeutic implications","volume":"391","author":"Leto","year":"2010","journal-title":"Biol Chem"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0565","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/00006676-199701000-00004","article-title":"Lysosomal aspartic and cysteine proteinases serum levels in patients with pancreatic cancer or pancreatitis","volume":"14","author":"Leto","year":"1997","journal-title":"Pancreas"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0570","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/sj.cgt.7700546","article-title":"Selective suppression of cathepsin L by antisense cDNA impairs human brain tumor cell invasion in vitro and promotes apoptosis","volume":"10","author":"Levicar","year":"2003","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0575","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/nrc2228","article-title":"Emerging roles of proteases in tumour suppression","volume":"7","author":"Lopez-Otin","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0580","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10585-008-9182-2","article-title":"The tumor microenvironment and metastatic disease","volume":"26","author":"Lunt","year":"2009","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0585","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/S1368-8375(03)00034-4","article-title":"Quantitative analysis of cathepsin L mRNA and protein expression during oral cancer progression","volume":"39","author":"Macabeo-Ong","year":"2003","journal-title":"Oral Oncol"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0590","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0014-5793(90)81151-D","article-title":"Susceptibility of the cartilage collagens types II, IX and XI to degradation by the cysteine proteinases, cathepsins B and L","volume":"269","author":"Maciewicz","year":"1990","journal-title":"FEBS Lett"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0595","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0165-4608(00)00278-8","article-title":"Molecular and cytogenetic analysis of glioblastoma multiforme","volume":"122","author":"Mao","year":"2000","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0600","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1042\/bj2480449","article-title":"The identification of the major excreted protein (MEP) from a transformed mouse fibroblast cell line as a catalytically active precursor form of cathepsin L","volume":"248","author":"Mason","year":"1987","journal-title":"Biochem J"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0605","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1042\/bj2330925","article-title":"Elastinolytic activity of human cathepsin L","volume":"233","author":"Mason","year":"1986","journal-title":"Biochem J"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0610","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.tcb.2010.12.002","article-title":"Proteolytic networks in cancer","volume":"21","author":"Mason","year":"2011","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0615","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3816\/CBC.2006.n.021","article-title":"Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors","volume":"7","author":"Mincey","year":"2006","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0620","first-page":"1109","article-title":"Cathepsin L is highly expressed in gastrointestinal stromal tumors","volume":"39","author":"Miyamoto","year":"2011","journal-title":"Int J Oncol"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0625","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/nrc1949","article-title":"Cysteine cathepsins: multifunctional enzymes in cancer","volume":"6","author":"Mohamed","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0630","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/ijc.10510","article-title":"Expression of N-terminally truncated isoforms of CDP\/CUX is increased in human uterine leiomyomas","volume":"100","author":"Moon","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0635","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0640","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s004180000162","article-title":"Immunohistochemical detection of cathepsin D, K, and L in the process of endochondral ossification in the human","volume":"114","author":"Nakase","year":"2000","journal-title":"Histochem Cell Biol"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0645","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1017\/S0022215112001995","article-title":"Prognostic value of cathepsin L and its inhibitor headpin in oral squamous cell carcinoma","volume":"126","author":"Nakashima","year":"2012","journal-title":"J Laryngol Otol"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0650","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1023\/A:1018496625936","article-title":"Inhibition of carcinoma cell invasion and liver metastases formation by the cysteine proteinase inhibitor E-64","volume":"15","author":"Navab","year":"1997","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0655","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.ejca.2010.02.041","article-title":"Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease","volume":"46","author":"Neville-Webbe","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0660","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/00006676-200410000-00005","article-title":"Prognostic impact of cysteine proteases cathepsin B and cathepsin L in pancreatic adenocarcinoma","volume":"29","author":"Niedergethmann","year":"2004","journal-title":"Pancreas"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0665","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/0006-291X(81)91275-4","article-title":"Stimulation of the release of two glycoproteins from mouse 3T3 cells by growth factors and by agents that increase intralysosomal pH","volume":"101","author":"Nilsen-Hamilton","year":"1981","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0670","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1006\/gyno.1995.1063","article-title":"Increased cathepsin L levels in serum in some patients with ovarian cancer: comparison with CA125 and CA72-4","volume":"56","author":"Nishida","year":"1995","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0675","doi-asserted-by":"crossref","first-page":"7893","DOI":"10.1074\/jbc.M610107200","article-title":"Interaction between human cathepsins K, L, and S and elastins: mechanism of elastinolysis and inhibition by macromolecular inhibitors","volume":"282","author":"Novinec","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0680","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nrclinonc.2010.134","article-title":"Future directions of bone-targeted therapy for metastatic breast cancer","volume":"7","author":"Onishi","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0685","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/nrc884","article-title":"Strategies for MMP inhibition in cancer: innovations for the post-trial era","volume":"2","author":"Overall","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0690","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.tips.2007.10.011","article-title":"Cysteine cathepsin proteases as pharmacological targets in cancer","volume":"29","author":"Palermo","year":"2008","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0695","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3346\/jkms.1996.11.2.144","article-title":"Enhanced expression of cathepsin L in metastatic bone tumors","volume":"11","author":"Park","year":"1996","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0700","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.gde.2007.12.001","article-title":"Application of activity-based probes to the study of enzymes involved in cancer progression","volume":"18","author":"Paulick","year":"2008","journal-title":"Curr Opin Genet Dev"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0705","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1096\/fj.05-5517fje","article-title":"Lysosomal, cytoskeletal, and metabolic alterations in cardiomyopathy of cathepsin L knockout mice","volume":"20","author":"Petermann","year":"2006","journal-title":"FASEB J"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0710","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1200\/JCO.2000.18.7.1570","article-title":"Osteoporosis due to cancer treatment: pathogenesis and management","volume":"18","author":"Pfeilschifter","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0715","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.0959-9673.2004.00373.x","article-title":"Cathepsin L-deficient mice exhibit abnormal skin and bone development and show increased resistance to osteoporosis following ovariectomy","volume":"85","author":"Potts","year":"2004","journal-title":"Int J Exp Pathol"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0720","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1083\/jcb.110.2.319","article-title":"Modulation of the transport of a lysosomal enzyme by PDGF","volume":"110","author":"Prence","year":"1990","journal-title":"J Cell Biol"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0725","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1073\/pnas.83.2.357","article-title":"The tumor promoter phorbol 12-myristate 13-acetate induces a program of altered gene expression similar to that induced by platelet-derived growth factor and transforming oncogenes","volume":"83","author":"Rabin","year":"1986","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0730","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.pharmthera.2012.02.005","article-title":"Novel therapies in benign and malignant bone diseases","volume":"134","author":"Rachner","year":"2012","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0735","doi-asserted-by":"crossref","first-page":"25103","DOI":"10.1074\/jbc.R109.041087","article-title":"Cellular and molecular mechanisms of bone remodeling","volume":"285","author":"Raggatt","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0740","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1530\/eje.0.1370209","article-title":"Glucocorticoid osteoporosis\u2014mechanisms and management","volume":"137","author":"Reid","year":"1997","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0745","doi-asserted-by":"crossref","first-page":"e3627","DOI":"10.1371\/journal.pone.0003627","article-title":"Osteoclasts are active in bone forming metastases of prostate cancer patients","volume":"3","author":"Roato","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0750","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0755","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1023\/A:1023007717757","article-title":"Pericellular cathepsin B and malignant progression","volume":"22","author":"Roshy","year":"2003","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0760","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/0006-291X(89)91755-5","article-title":"Membrane-associated cathepsin L: a role in metastasis of melanomas","volume":"164","author":"Rozhin","year":"1989","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0765","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.chembiol.2007.03.010","article-title":"Design, synthesis, and evaluation of in vivo potency and selectivity of epoxysuccinyl-based inhibitors of papain-family cysteine proteases","volume":"14","author":"Sadaghiani","year":"2007","journal-title":"Chem Biol"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0770","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1533-869X.2003.01105.x","article-title":"Regulation of cathepsin B and L expression in vitro in gastric cancer tissues by egg cystatin","volume":"3","author":"Saleh","year":"2003","journal-title":"J Exp Ther Oncol"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0775","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1111\/j.1582-4934.2010.01203.x","article-title":"Epigenetic regulation of cathepsin L expression in chronic myeloid leukaemia","volume":"15","author":"Samaiya","year":"2011","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0780","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1038\/sj.gt.3302265","article-title":"Targeting cathepsin L (CL) by specific ribozymes decreases CL protein synthesis and cartilage destruction in rheumatoid arthritis","volume":"11","author":"Schedel","year":"2004","journal-title":"Gene Ther"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0785","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1128\/MCB.3.1.70","article-title":"Identification of a BALB\/c-3T3 cell protein modulated by platelet-derived growth factor","volume":"3","author":"Scher","year":"1983","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0790","first-page":"4757","article-title":"Correlation of high lactate levels in human cervical cancer with incidence of metastasis","volume":"55","author":"Schwickert","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0795","first-page":"3809","article-title":"Cysteine protease activities and tumor development in human colorectal carcinoma","volume":"49","author":"Sheahan","year":"1989","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0800","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1038\/sj.onc.1207340","article-title":"Cystatin M suppresses the malignant phenotype of human MDA-MB-435S cells","volume":"23","author":"Shridhar","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0805","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.pharmthera.2015.06.006","article-title":"Modulation of the tumor vasculature and oxygenation to improve therapy","volume":"153","author":"Siemann","year":"2015","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0810","first-page":"189","article-title":"Determination of cysteine peptidases-like activity and their inhibitors in the serum of patients with ovarian cancer treated by conventional chemotherapy and vitamin E","volume":"4","author":"Siewinski","year":"2004","journal-title":"J Exp Ther Oncol"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0820","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3109\/07357907.2013.820318","article-title":"Prognostic significance of extracellular matrix degrading enzymes-cathepsin L and matrix metalloproteases-2 [MMP-2] in human pancreatic cancer","volume":"31","author":"Singh","year":"2013","journal-title":"Cancer Invest"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0825","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/BF00157683","article-title":"Expression and immunohistochemical localization of cathepsin L during the progression of human gliomas","volume":"14","author":"Sivaparvathi","year":"1996","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0830","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3109\/07357907.2012.672608","article-title":"Expression of cysteine protease cathepsin L is increased in endometrial cancer and correlates with expression of growth regulatory genes","volume":"30","author":"Skrzypczak","year":"2012","journal-title":"Cancer Invest"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0835","doi-asserted-by":"crossref","first-page":"7900","DOI":"10.1038\/sj.onc.1203334","article-title":"BRCA1 deficient embryonic stem cells display a decreased homologous recombination frequency and an increased frequency of non-homologous recombination that is corrected by expression of a brca1 transgene","volume":"18","author":"Snouwaert","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0840","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/03009740701340172","article-title":"Cysteine and serine proteases of synovial tissue in rheumatoid arthritis and osteoarthritis","volume":"36","author":"Solau-Gervais","year":"2007","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0845","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1016\/j.bmcl.2012.12.025","article-title":"Small-molecule inhibitors of cathepsin L incorporating functionalized ring-fused molecular frameworks","volume":"23","author":"Song","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0850","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/0003-9861(90)90666-M","article-title":"Comparison of cathepsin L synthesized by normal and transformed cells at the gene, message, protein, and oligosaccharide levels","volume":"283","author":"Stearns","year":"1990","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0855","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1073\/pnas.092637699","article-title":"Dilated cardiomyopathy in mice deficient for the lysosomal cysteine peptidase cathepsin L","volume":"99","author":"Stypmann","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0860","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s10585-013-9590-9","article-title":"Cathepsin L inhibition by the small molecule KGP94 suppresses tumor microenvironment enhanced metastasis associated cell functions of prostate and breast cancer cells","volume":"30","author":"Sudhan","year":"2013","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0870","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.pan.2012.07.011","article-title":"Cathepsins and pancreatic cancer: the 2012 update","volume":"12","author":"Sulpizio","year":"2012","journal-title":"Pancreatology"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0865","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.pan.2012.07.011","article-title":"Update","volume":"12","author":"Sulpizio","year":"2012","journal-title":"Pancreatology"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0875","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.juro.2007.09.037","article-title":"Role of urinary cathepsin B and L in the detection of bladder urothelial cell carcinoma","volume":"179","author":"Svatek","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0880","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/0014-5793(94)80522-9","article-title":"The mechanisms and regulation of procathepsin L secretion from osteoclasts in bone resorption","volume":"342","author":"Tagami","year":"1994","journal-title":"FEBS Lett"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0885","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4331\/wjbc.v4.i4.91","article-title":"Cathepsins mediate tumor metastasis","volume":"4","author":"Tan","year":"2013","journal-title":"World J Biol Chem"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0890","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00109-008-0423-2","article-title":"Lysosomal cysteine peptidase cathepsin L protects against cardiac hypertrophy through blocking AKT\/GSK3beta signaling","volume":"87","author":"Tang","year":"2009","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0895","first-page":"2173","article-title":"Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L","volume":"18","author":"Thomssen","year":"1998","journal-title":"Anticancer Res"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0900","first-page":"741","article-title":"Prognostic value of the cysteine proteases cathepsins B and cathepsin L in human breast cancer","volume":"1","author":"Thomssen","year":"1995","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0905","doi-asserted-by":"crossref","first-page":"696","DOI":"10.2174\/156802610791113441","article-title":"Development of cathepsin inhibitors and structure-based design of cathepsin B-specific inhibitor","volume":"10","author":"Tomoo","year":"2010","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0910","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1016\/j.bmcl.2013.03.041","article-title":"Identification of new peptide amides as selective cathepsin L inhibitors: the first step towards selective irreversible inhibitors?","volume":"23","author":"Torkar","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0915","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1042\/bj2460731","article-title":"Sequence and expression of the cDNA for MEP (major excreted protein), a transformation-regulated secreted cathepsin","volume":"246","author":"Troen","year":"1987","journal-title":"Biochem J"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0920","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.ejca.2004.03.011","article-title":"Expression of Cathepsin B and L antigen and activity is associated with early colorectal cancer progression","volume":"40","author":"Troy","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0925","first-page":"2315","article-title":"Cathepsin D, B and L circulating levels as prognostic markers of malignant progression","volume":"16","author":"Tumminello","year":"1996","journal-title":"Anticancer Res"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0930","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/nrd2092","article-title":"Targeting proteases: successes, failures and future prospects","volume":"5","author":"Turk","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0935","first-page":"1375","article-title":"Human cysteine proteinases and their protein inhibitors stefins, cystatins and kininogens","volume":"45","author":"Turk","year":"1986","journal-title":"Biomed Biochim Acta"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0940","doi-asserted-by":"crossref","first-page":"4629","DOI":"10.1093\/emboj\/20.17.4629","article-title":"Lysosomal cysteine proteases: facts and opportunities","volume":"20","author":"Turk","year":"2001","journal-title":"EMBO J"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0945","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3322\/caac.20103","article-title":"Aging and osteoporosis in breast and prostate cancer","volume":"61","author":"VanderWalde","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0950","doi-asserted-by":"crossref","first-page":"14726","DOI":"10.1021\/ja4056068","article-title":"Improved quenched fluorescent probe for imaging of cysteine cathepsin activity","volume":"135","author":"Verdoes","year":"2013","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0955","first-page":"916","article-title":"High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers","volume":"60","author":"Walenta","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0960","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1128\/MCB.23.7.2556-2563.2003","article-title":"p53 Binding protein 53BP1 is required for DNA damage responses and tumor suppression in mice","volume":"23","author":"Ward","year":"2003","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0965","first-page":"120","article-title":"Elevation of tissue cathepsin B and L activities in gastric cancer","volume":"34","author":"Watanabe","year":"1987","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0970","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0885-4505(89)90037-6","article-title":"Cathepsin B and L activities in gastric cancer tissue: correlation with histological findings","volume":"42","author":"Watanabe","year":"1989","journal-title":"Biochem Med Metab Biol"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0975","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1007\/BF01221037","article-title":"Hybridoma cells producing antibodies to cathepsin L have greatly reduced potential for tumour growth","volume":"120","author":"Weber","year":"1994","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0980","first-page":"102","article-title":"Expression of cathepsin L in nasopharyngeal carcinoma and its clinical significance","volume":"31","author":"Xu","year":"2009","journal-title":"Exp Oncol"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0985","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/jcp.21517","article-title":"IL-6\/sIL-6R enhances cathepsin B and L production via caveolin-1-mediated JNK-AP-1 pathway in human gingival fibroblasts","volume":"217","author":"Yamaguchi","year":"2008","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0990","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1177\/147323001003800604","article-title":"Cathepsin L is associated with proliferation and clinical outcome of urothelial carcinoma of the bladder","volume":"38","author":"Yan","year":"2010","journal-title":"J Int Med Res"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb0995","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1475-2867-7-8","article-title":"Cathepsin L increases invasion and migration of B16 melanoma","volume":"7","author":"Yang","year":"2007","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb1000","doi-asserted-by":"crossref","first-page":"9590","DOI":"10.1073\/pnas.1531542100","article-title":"Cathepsin L in secretory vesicles functions as a prohormone-processing enzyme for production of the enkephalin peptide neurotransmitter","volume":"100","author":"Yasothornsrikul","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb1005","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0304-3835(02)00452-4","article-title":"Expression of cysteine peptidase cathepsin L and its inhibitors stefins A and B in relation to tumorigenicity of breast cancer cell lines","volume":"187","author":"Zajc","year":"2002","journal-title":"Cancer Lett"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb1010","first-page":"7883","article-title":"Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone","volume":"63","author":"Zhang","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb1015","first-page":"3423","article-title":"Clinical value of combined detection of serum matrix metalloproteinase-9, heparanase, and cathepsin for determining ovarian cancer invasion and metastasis","volume":"31","author":"Zhang","year":"2011","journal-title":"Anticancer Res"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb1020","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1158\/0008-5472.CAN-03-0820","article-title":"Senescence-initiated reversal of drug resistance: specific role of cathepsin L","volume":"64","author":"Zheng","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb1025","doi-asserted-by":"crossref","first-page":"C65","DOI":"10.1152\/ajpcell.00082.2008","article-title":"Cathepsin L inhibition suppresses drug resistance in vitro and in vivo: a putative mechanism","volume":"296","author":"Zheng","year":"2009","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb1030","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.4161\/cbt.8.24.10353","article-title":"Selective matrix metalloproteinase (MMP) inhibitors in cancer therapy: ready for prime time?","volume":"8","author":"Zucker","year":"2009","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.pharmthera.2015.08.007_bb1035","doi-asserted-by":"crossref","first-page":"6642","DOI":"10.1038\/sj.onc.1204097","article-title":"Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment","volume":"19","author":"Zucker","year":"2000","journal-title":"Oncogene"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725815001655?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725815001655?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T13:59:09Z","timestamp":1653055149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725815001655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":204,"alternative-id":["S0163725815001655"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2015.08.007","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cathepsin L targeting in cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2015.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}